Racemic mixtures and enantiomerically pure D-isomers of both myo-inositol 1,3,6-trisphosphorothioate [Ins(1, 3, 6)PS 3 ] and myo-inositol 1,4,6-trisphosphorothioate [Ins(1,4,6)PS 3 ], prepared by total synthesis, were examined in Ca 2ϩ flux and binding assays. Both 3, 6)PS 3 and D-Ins(1,4,6)PS 3 were shown to be low intrinsic activity partial agonists at the platelet myo-inositol 1,4,5-trisphosphate [Ins(1,4,5)P 3 ] receptor, releasing less than 20% of the Ins(1,4,5)P 3 -sensitive Ca 2ϩ store. D-Ins(1,4,6)PS 3 displaced specifically bound [ 3, 6)PS 3 or D-Ins(1,4,6)PS 3 were able to partially antagonize Ca 2ϩ release induced by submaximal concentrations of Ins(1,4,5)P 3 , an inhibition that could be overcome by increasing the concentration of Ins(1,4,5)P 3 , suggesting competition for binding at the Ins(1,4,5)P 3 -R. The only low-efficacy partial agonists at the Ins(1,4,5)P 3 -R discovered to date have been phosphorothioates; the novel D-Ins(1,3,6)PS 3 and D-Ins(1,4,6)PS 3 can now be added to this small group of analogs. However, D-Ins(1,4,6)PS 3 has a relatively high affinity for the Ins(1,4,5)P 3 -R but maintains the lowest efficacy of all the partial agonists thus far identified. As such, it may be a useful tool for pharmacological intervention in the polyphosphoinositide pathway and an important lead compound for the development of further Ins(1,4,5)P 3 -R antagonists.
An elevated level of cytosolic Ca 2ϩ is known to be a principle mediator of activation-response coupling in numerous cell types in response to a wide range of extracellular stimuli. In non-voltage-excitable cells, Ca 2ϩ is elevated via two pathways: mobilization from the intracellular stores and influx across the plasma membrane (Berridge, 1993; Putney and Bird, 1993; Clapham, 1995) . Agonist-receptor coupling activates the hydrolysis of phosphatidylinositol 4,5-bisphosphate, producing the signal molecule inositol 1,4,5-trisphosphate [Ins(1,4,5)P 3 ], which, via ligation of specific receptors on Ins(1,4,5)P 3 -sensitive intracellular Ca 2ϩ stores, induces Ca 2ϩ mobilization into the cytoplasm, (for review, see Patel et al., 1999) . Three Ins(1,4,5)P 3 -receptor [Ins(1,4,5)P 3 -R] subtypes, together with splice variants of each of these, have now been identified and the genes cloned (Furuichi et al., 1989; Sudhof et al., 1991; Blondel et al., 1993) . The Ins(1,4,5)P 3 -R is now known to exist as a heterotetrameric complex that forms the Ins(1,4,5)P 3 -gated Ca 2ϩ channel (Joseph et al., 1995; Monkawa et al., 1995; Wojcikiewicz and He, 1995) . Expression of the Ins(1,4,5)P 3 -R was found to enhance both Ins(1,4,5)P 3 binding and Ca 2ϩ -releasing activities in transfected cell lines, indicating expression of protein with both binding sites for Ins(1,4,5)P 3 and Ca 2ϩ channel activity (Miyawaki et al., 1990) .
To investigate the relative importance of Ins(1,4,5)P 3 -induced Ca 2ϩ release in mediating the physiological processes within cells, a specific, high-affinity Ins(1,4,5)P 3 -R antagonist is required. In the rational design of an Ins(1,4,5)P 3 -R antagonist or a low intrinsic activity partial agonist, extensive knowledge of the structure-activity relationships of Ins(1,4,5)P 3 is required (for review, see Wilcox et al., 1998) . At present, structure-activity studies using analogs of Ins(1,4,5)P 3 have not identified any distinct structural motifs of Ins(1,4,5)P 3 that are responsible solely for either its receptor binding capability or its Ca 2ϩ -releasing activity (Potter and Lampe, 1995) , although the pivotal role of the vicinal 4,5-trisphosphate system augmented by other auxiliary motifs has long been recognized.
The first inositol phosphate demonstrated to be a partial agonist at the Ins(1,4,5)P 3 -R was the naturally occurring higher polyphosphate myo-inositol 1, 3, 4, 3, 4, 6) P 4 ] in SH-SY5Y cells (Gawler et al., 1991) , although this compound was a full agonist in rabbit platelets (Murphy et al., 1996) . L-chiro-Inositol 2, 3, 3, 5) PS 3 ] and D-6-deoxy-myo-inositol 1,4,5-trisphosphorothioate [6-deoxy-Ins(1,4,5)PS 3 ] (Fig. 1a) were found to be lowefficacy partial agonists at the Ins(1,4,5)P 3 -R Liu et al., 1994) . L-chr-Ins(2,3,5)PS 3 and 6-deoxyIns(1,4,5)PS 3 are the C-3-and C-6-modified analogs of Ins(1,4,5)P 3, respectively, in addition to carrying phosphorothioate groups rather than phosphates at the 1-, 4-and 5-positions. A high intrinsic activity partial agonist scyllo-inositol 1,2,4,5-tetrakisphosphorothioate also combined phosphorothioate substitutions at the key vicinal 4,5-bisphosphate motif with further structural modifications . Replacement of all the phosphate groups on Ins(1,4,5)P 3 with phosphorothioate groups, with no other perturbation of the molecular structure of Ins(1,4,5)P 3 , however, had no effect on efficacy and only a small decrease in affinity at the Ins(1,4,5)P 3 -R in numerous cell types (for review, see Potter and Nahorski, 1992) . Most recently, D-3-fluoro-myo-inositol 1-phosphate-4,5-bisphosphorothioate [3F-Ins(1)P-(4,5)PS 2 ] (Fig. 1a) was found to be only 10-fold less potent than Ins(1,4,5)P 3 at displacing [ 3 H]Ins(1,4,5)P 3 from its receptor on pig cerebellum and to mobilize up to 60% of total Ca 2ϩ in permeabilized SH-SY5Y cells . Therefore, all of the partial agonists thus far described at the Ins(1,4,5)P 3 -R are Ins(1,4,5)P 3 analogs and, with the exception of scyllo-inositol 1,2,4,5-tetrakisphosphorothioate and Ins(1,3,4,6)P 4 , have combined modifications at C-3 or C-6 with phosphorothioate substitutions.
The Ca 2ϩ -mobilizing activity of Ins(1,3,4,6)P 4 was rationalized by envisaging two alternative receptor-binding orientations in which the 1,6-vicinal bisphosphate of Ins(1,3,4,6)P 4 mimics the normal 4,5-bisphosphate in the Ins(1,4,5)P 3 binding orientation (although this did not explain its partial agonist properties). This model predicted that two Ins(1,4,5)P 3 regioisomers (i.e., D-myo-inositol 1,4,6-trisphosphate [D-Ins(1,4,6)P 3 ] and D-myo-inositol 1, 3, 3, 6 )P 3 {L-Ins(1,3,4)P 3 1 }]) should be able to mobilize Ca 2ϩ and indeed this was confirmed . Both of these active enantiomers possess one of the features found in the majority of partial agonists: a modification at either the C-3 or C-6 groups. The other characteristic feature found in common in the partial agonists is the replacement of the vicinal 4,5-bisphosphate group with phosphorothioate groups. To determine whether adoption of these minimal criteria, found in common with other partial agonists, was adequate in the rational design of a partial agonist, we replaced the phosphate groups of both Ins(1,3,6)P 3 and Ins(1,4,6)P 3 with phosphorothioates in the synthesis of Ins(1,3,6)PS 3 and Ins(1,4,6)PS 3 . Preliminary data suggested that the racemic mixtures of the phosphorothioates Ins(1,4,6)PS 3 and Ins(1, 3, 6 )PS 3 ( Fig. 1a) were partial agonists at the Ins(1,4,5)P 3 -R in permeabilized rabbit platelets (AlHafidh et al., 1994; Mills et al., 1995) . Using the same rationalization for the Ca 2ϩ -mobilizing activity of the partial agonist Ins(1,3,4,6)P 3 , we predicted that the two chiral phosphorothioate analogs, 3, 6 )PS 3 and D-Ins(1,4,6)PS 3 , were responsible for the observed partial agonist properties of their racemic mixtures. In this study, we demonstrate clearly that both of these phosphorothioate analogs are low-intrinsic-activity partial agonists at the Ins(1,4,5)P 3 -R and that one of them [D-Ins(1,4,6)PS 3 ] possesses particularly promising potency coupled with very low intrinsic activity.
Experimental Procedures Materials
Chemically synthesized Ins(1,4,5)P 3 was purchased from the Rhode Island Chemical Group (Kingston, RI). shire, UK). FP100 filters were purchased from Whatman (Clifton, NJ). Saponin A, oligomycin, leupeptin, pepstatin, and ATP were obtained from Sigma (St. Louis, MO), ionomycin was purchased from Calbiochem (San Diego, CA). 3, 6 )PS 3 and DL-Ins(1,4,6)PS 3 were synthesized as described by Mills et al. (1995) . 3, 6 )PS 3 was synthesized from 1D-2,4,5-tri-O-benzyl-myo-inositol (Riley et al., 1994) and D-Ins(1,4,6)PS 3 was synthesized from 1D-2,3,5-tri-O-benzyl myo-inositol using methods similar to those described for the racemic mixture (Mills et al., 1995) . All synthetic compounds were homogenous by 1 H and 31 P NMR spectroscopy and mass spectroscopy after purification by ion-exchange chromatography. The compounds were quantified by total phosphate assay and then used as their triethylammonium salts.
Methods
Preparation of Platelets. Washed rabbit platelets were prepared as described previously (Murphy et al., 1991) . The resulting platelet pellet from this preparation was resuspended in HEPESbuffered Tyrode's solution (10 mM HEPES, 145 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 0.5 mM Na 2 HPO 4 , 5.5 mM glucose and 0.25% BSA, pH 7.4) before performing the following procedures.
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2؉ Release from Intracellular Stores. Platelets were washed in high-K ϩ buffer A [120 mM KCl, 2 mM KH 2 PO 4 , 5 mM (CH 2 COONa) 2 .6H 2 O, 6 mM MgCl 2 , 20 mM HEPES, in MilliQ water; 5 mM ATP was added, pH adjusted to 6.9 and free Ca 2ϩ concentration adjusted below 150 nM] and then suspended to 3 ϫ 10 9 /ml. The platelets were then permeabilized with 40 g/ml saponin A, which was removed by further washing in buffer A. H]Ins(1,4,5)P 3 bound to the Ins(1,4,5)P 3 receptors on the membranes was performed as described previously (Challiss et al., 1991) . Briefly, cerebella were removed from 6 rats (200-250 g) and homogenized (2 ϫ 10 s, 4°C) in buffer C (20 mM Tris ⅐ HCl, 20 mM NaCl, 100 mM KCl, 1 mM EDTA, 1 mg/ml BSA, pH 7.7) containing the protease inhibitors 10 M leupeptin and 10 M pepstatin. After centrifugation (50,000g, 13 min, 4°C), the pellet was resuspended in buffer C, homogenized as above, and the protein content adjusted to 5 mg/ml. The cerebellar membranes were either used immediately or frozen (Ϫ80°C) until use. The binding assay mixture in a total volume of 250 l contained 1 nM [ 3 H]Ins(1,4,5)P 3 , and synthetic ligand diluted in buffer C at appropriate concentrations. Binding was initiated by the addition of 250 g of the cerebellar membrane preparation. The assay tubes were incubated (4°C) for 10 min before termination of the reaction by centrifugation (10,000g, 4 min, 4°C). Nonspecific binding of [ 3 H]Ins(1,4,5)P 3 was assessed as the counts remaining upon inclusion of 10 M cold Ins(1,4,5)P 3 in the assay mixture. After centrifugation, the supernatant was carefully removed, the pellet resuspended, and radioactivity bound to the cerebellar membrane was determined by liquid scintillation counting. (Fig. 2) . DLIns(1,3,6)PS 3 (1-3000 M) alone caused a dose-dependent release of 45 
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2ϩ from the stores of permeabilized platelets. Maximal release, however, was only around 20% of the Ins(1,4,5)P 3 -sensitive Ca 2ϩ pool, even at concentrations above 1 mM (some of which may have been caused by nonspecific release), demonstrating a very low efficacy for 3, 6 )PS 3 at the Ins(1,4,5)P 3 -R of rabbit platelets (Fig. 2a) . Treatment of permeabilized platelets with 1 M Ins(1,4,5)P 3 , together with increasing concentrations of DL-Ins(1,3,6)PS 3 , caused an inhibition of Ins(1,4,5)P 3 -induced Ca 2ϩ -release (Fig. 2a) . Ca 2ϩ release induced by Ins(1,4,5)P 3 was reduced as the concentration of DLIns(1,3,6)PS 3 increased, until release approached a level near the intrinsic efficacy of 3, 6 )PS 3 itself. The concentration of 3, 6 )PS 3 required to inhibit release of Ca 2ϩ induced with 1 M Ins(1,4,5)P 3 by 50% (IC 50 ) was Ͼ100 M. However, increasing the concentration of 3, 6 )PS 3 to -release induced with 1 M Ins(1,4,5)P 3 is reached by 100 M (Fig. 2a) .
DL-Ins(1,4,6)PS 3 (0.03-300 M) was also found to have a very low efficacy at the Ins(1,4,5)P 3 -R, releasing only ϳ15% of the Ins(1,4,5)P 3 -sensitive Ca 2ϩ store at the highest concentration used (300 M) (Fig. 2b) . However, Ca 2ϩ release induced by 1 M Ins(1,4,5)P 3 could be inhibited with increasing concentrations of DL-Ins(1,4,6)PS 3 (Fig. 2b) . As described previously for DL-Ins(1,3,6)PS 3 , Ca 2ϩ release induced by Ins(1,4,5)P 3 was further inhibited as the concentration of DL-Ins(1,4,6)PS 3 increased, until release declined to a level near the intrinsic efficacy of DL-Ins(1,4,6)PS 3 itself. The concentration of DL-Ins(1,4,6)PS 3 required to inhibit release of Ca 2ϩ induced with 1 M Ins(1,4,5)P 3 by 50% (IC 50 ) was found to be 56 Ϯ 3.6 M. Maximal inhibition of Ca 2ϩ -release induced by 1 M Ins(1,4,5)P 3 seems to have been achieved with 100 M DL-Ins(1,4,6)PS 3 as an increased Ca 2ϩ release was observed with 300 M (Fig. 2b) .
Displacement of Specific [ 3 H]Ins(1,4,5)P 3 Binding to Rat Cerebellar Membranes. [
3 H]Ins(1,4,5)P 3 was readily displaced from specific binding sites on rat cerebellar membranes by cold D-Ins(1,4,5)P 3 with an IC 50 of 0.043 Ϯ 0.01 M (Fig. 3) . The ability of DL-and D-Ins(1,3,6)PS 3 and of DL-and D-Ins(1,4,6)PS 3 to displace [
3 H]Ins(1,4,5)P 3 from rat cerebellar membranes was also examined (Fig. 3) . D-Ins(1,3,6)PS 3 displaced specifically bound [
3 H]Ins(1,4,5)P 3 from rat cerebellar membranes, although displacement by D-Ins(1,3,6)PS 3 was 500 fold weaker than by D-Ins(1,4,5)P 3 (Fig. 3a) . However, comparing the IC 50 value for D-Ins(1,3,6)PS 3 (17.5 Ϯ 5.8 M) with that of the racemic mixture DL-Ins(1,3,6)PS 3 (34 Ϯ 10 M), demonstrated that D-Ins(1,3,6)PS 3 was able to displace [ 3 H]Ins(1,4,5)P 3 with roughly twice the affinity of the racemic mixture, confirming that activity resides in the Denantiomer (Fig. 3a) . D-Ins(1,4,6)PS 3 displaced specifically bound [ 3 H]Ins(1,4,5)P 3 from rat cerebellar membranes, although displacement by D-Ins(1,4,6)PS 3 was some 34-fold weaker than by D-Ins(1,4,5)P 3 (Fig. 3a) . D-Ins(1,4,6)PS 3 was able to displace [ 3 H]Ins(1,4,5)P 3 from cerebellar membranes with roughly twice the affinity of its racemic mixture (IC 50 value of 1.4 Ϯ 0.35 M compared with an IC 50 value of 2.15 Ϯ 0.13 M for the racemic mixture), indicating that the activity resides in the D-enantiomer (Fig. 3b) .
Therefore, the ability of 3, 6 were also found to have a very low efficacy at the Ins(1,4,5)P 3 -receptor of platelets, releasing only a small percentage (Ͻ15%) of the Ins(1,4,5)P 3 -sensitive Ca 2ϩ store even at 300 M (Fig.  4a) . It is possible that the release of Ca 2ϩ by high concentrations of both 3, 6 )PS 3 and D-Ins(1,4,6)PS 3 may be nonspecific.
Increasing concentrations of 3, 6 )PS 3 (30, 100, and 300 M) were able to partially antagonize Ca 2ϩ release induced by submaximal concentrations of Ins(1,4,5)P 3 (0.1-3 M); however, by increasing the concentration of Ins(1,4,5)P 3 (10 and 30 M), this inhibition was no longer observed, suggesting competition for binding at the Ins(1,4,5)P 3 -R (Fig. 4b) . The IC 50 value for the inhibition of Ca 2ϩ elevation induced by 1 M Ins(1,4,5)P 3 was Ͼ100 M for D-Ins(1,3,6)PS 3 . Competitive partial antagonism of Ins(1,4,5)P 3 -induced Ca 2ϩ release was also observed with D-Ins(1,4,6)PS 3 (10, 30, and 100 M) (Fig. 4c) . The IC 50 value of D-Ins(1,4,6)PS 3 for Ca 2ϩ release induced by 1 M Ins(1,4,5)P 3 was 27 Ϯ 8.1 M, approximately half that required of the racemic mixture (56 Ϯ 3.6 M) .
Discussion
Structure-activity studies performed to date using Ins(1,4,5)P 3 analogs have concluded that the vicinal 4,5-bisphosphate configuration plays the key role in receptor recognition and mediation of Ca 2ϩ release from intracellular stores (for reviews, see Potter and Nahorski, 1992; Potter and Lampe, 1995; Wilcox et al., 1998) . Other structural require- ments for Ca 2ϩ release include an additional phosphate group at the 1-position (but it can be tolerated at the 2-position), which increases affinity at the Ins(1,4,5)P 3 -R (Potter and Lampe, 1995) . The importance of the hydroxyl groups of Ins(1,4,5)P 3 is well characterized, with modification of the three hydroxyl groups at either the 2-, 3-or 6-position of Ins(1,4,5)P 3 varying the impact on Ca 2ϩ release and the binding of Ins(1,4,5)P 3 to its receptor (for review, see Potter and Lampe, 1995) .
At present very few partial agonists at the Ins(1,4,5)P 3 -R have been reported; these include Ins(1,3,4,6)P 4 (Gawler et al., 1991) , L-chr-Ins(2,3,5)PS 3 , and 6-deoxy-Ins1,4,5)PS 3 , scyllo-inositol 1,2,4,5-tetrakisphosphorothioate , and 3F-Ins(1)P-(4,5)PS 2 . By using rapid kinetic measurements of 45 Ca 2ϩ mobilization, Ins(2,4,5)P 3 has also been demonstrated to be a partial agonist at hepatic Ins(1,4,5)P 3 -Rs (Marchant et al., 1997) . Because of the quantal mechanism of Ca 2ϩ release, whereby even partial agonists may completely empty the Ins(1,4,5)P 3 -sensitive Ca 2ϩ stores, albeit at slower rates than Ins(1,4,5)P 3 , it is possible that the partial agonist properties of other inositol phosphates may be distinguished under high temporal resolution (Menza and Michelangeli, 1998) . D-3-Amino-3-deoxy-Ins(1,4,5)P 3 has also been described as a partial agonist in SH-SY5Y neuroblastoma cells, but increasing pH from 6.8 to 7.2 negates the partial agonist properties (Kozikowski et al., 1994) .
In a previous study , we rationalized how Ins(1,3,4,6)P 4 elicits Ca 2ϩ release by envisaging two alternative receptor binding orientations, where the 1,6-vicinal bisphosphate is presumed to mimic the normal 4,5-bisphosphate of Ins(1,4,5)P 3 . As either the 4-phosphate or the 3-phosphate of Ins(1,3,4,6)P 4 could mimic the 1-phosphate of Ins(1,4,5)P 3 , it is likely that Ins(1,3,4,6)P 4 evokes Ca 2ϩ release by a similar binding mechanism to Ins(1,4,5)P 3 . We went on to show that two related trisphosphates 4, 6 )P 3 and D-Ins(1,3,6)P 3 ] were also able to displace [ 3 H]Ins(1,4,5)P 3 from the Ins(1,4,5)P 3 -R and to possess Ca 2ϩ mobilization ability, whereas their enantiomers were inactive . Noting that Ins(1,4,6)P 3 and Ins(1,3,6)P 3 possessed one of the features common to the known partial agonist, namely modification at some of the positions corresponding to C-2, C-3, or C-6 of Ins(1,4,5)P 3 , we went on to replace their phosphate groups with phosphorothioates, giving Ins(1,4,6)PS 3 and Ins(1, 3, 6 )PS 3 . From the preceding structure-activity arguments, we predicted that 4, 6 )PS 3, 6 )PS 3 would show partial agonist properties, whereas their enantiomers would be inactive.
Both the racemic trisphosphorothioates 3, 6 )PS 3 and DL-Ins(1,4,6)PS 3 were found to have very low efficacy at the Ins(1,4,5)P 3 -R of rabbit platelets. Taken in isolation, this result does not show that either of these compounds is a partial agonist; an extremely-low-potency full agonist could give similar results. However, when platelets were treated with 1 M Ins(1,4,5)P 3 , together with increasing concentrations of either 3, 6 )PS 3 or DL-Ins(1,4,6)PS 3 , a definite inhibition of Ins(1,4,5)P 3 -stimulated Ca 2ϩ release was observed, demonstrating that both 3, 6 )PS 3 and DLIns(1,4,6)PS 3 were acting as true partial agonists.
It was assumed that the partial agonist activity of racemic 4, 6 3-deoxy-myo-inositol 1,5-bisphosphate-4-phosphorothioate, D-3-fluoro-3-deoxy-myo-inositol 1,4-bisphosphate-5-phosphorothioate, and 3F-Ins(1)P-(4,5)PS 2 for partial agonist activity . Similarly to D-Ins(1,4,6)PS 3 , these compounds possessed a structural perturbation at the hydroxyl group that mimics the 3-OH of Ins(1,4,5)P 3 . This was achieved by the replacement of the native 3-OH with a fluorine group. Again, like D-Ins(1,4,6)PS 3 , these compounds had phosphorothioate substitutions, although only one, 3F-Ins(1)P-(4,5)PS 2 , had phosphorothioate substitutions at both members of the crucial vicinal 4,5-bisphosphate motif. Of these compounds, 3F-Ins(1)P-(4,5)PS 2 was the only one identified as a partial agonist, able to inhibit Ca 2ϩ mobilization induced by submaximal concentrations of Ins(1,4,5)P 3 . It was also demonstrated to be an antagonist of receptor-mediated Ca 2ϩ signaling (Davis et al., 1998) . Compared with 3F-Ins(1)P-(4,5)PS 2 , D-Ins(1,4,6)PS 3 has a lower affinity for the Ins(1,4,5)P 3 -R [it is ϳ34-fold weaker than Ins(1,4,5)P 3 at displacing [ 3 H]Ins(1,4,5)P 3 ], whereas 3F-Ins(1)P-(4,5)PS 2 was only 10-fold weaker . Of all the phosphorothioatecontaining partial agonists, 3-F-Ins(1)P-(4,5)P 2 is the only one that has not substituted the ("pseudo")-1-phosphate with a phosphorothioate; this may account for its increased affinity above the other partial agonists described so far. However, compared with D-Ins(1,4,6)PS 3 , 3F-Ins(1)P-(4,5)PS 2 , has a relatively high efficacy, causing over 60% of Ca 2ϩ to be released. Therefore, although 3F-Ins(1)P-(4,5)PS 2 has a high affinity, its potential as a partial antagonist and a lead compound is reduced by its higher efficacy. It is possible, therefore, that the lower affinity of 4, 6 )PS 3 at the Ins(1,4,5)P 3 -R compared with 3F-Ins(1)P-(4,5)PS 2 is because it has three phosphorothioates, one of which is at the 1-position. Thus a version of D-Ins(1,4,6)PS 3 with a vicinal bisphosphorothioate and a pseudo-1-phosphate [namely D-Ins(4)P-(1,6)PS 2 ] may combine the high affinity of 3F-Ins(1)P-(4,5)PS 2 and the low efficacy of D-Ins(1,4,6)PS 3 .
The only low-efficacy partial agonists at the Ins(1,4,5)P 3 -R discovered to date have been phosphorothioates; 3, 6 )PS 3 and D-Ins(1,4,6)PS 3 now expand this small group of such analogs. However, 4, 6 )PS 3 in particular has a relatively high affinity for the Ins(1,4,5)P 3 receptor and yet maintains very low efficacy. Thus D-Ins(1,4,6)PS 3 may be a useful tool for pharmacological intervention in the polyphosphoinositide pathway and an important lead compound for the development of Ins(1,4,5)P 3 receptor antagonists. Indeed, it has recently been successfully employed via microinjection to inhibit Ins(1,4,5)P 3 -induced Ca 2ϩ mobilization in intact Jurkat T-lymphocytes (Guse et al., 1997 (Guse et al., , 1999 .
